Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024
Executive Summary
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?
Placebo Response Hurts MoonLake In Psoriatic Arthritis
Sonelokimab follows a mid-stage slam-dunk in hidradenitis suppurativa with a rather more equivocal result in a different immune condition in the ARGO study.
Gilead And AbbVie Are Not The Only Ones Re-Thinking CD47 Immunotherapies
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.